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The eldery constituted the fast growing segment of the end-stage
renal disease (ESRD) population. However, the information about the
elderly patients on hemodilaysis therapy is limited. We investigated
outcomes and the prognostic factors for elderly patients who initiated
hemodialysis.
We reviewed medical recodes and conducted survival analysis in elderly
patients over than 75 years when they had started hemodialysis in single
center between 1988 and 2010. We analyzed the survival time of elderly
hemodialysis patients with Korean national health insurance data system.
Sixty hundred and sixty eight patients initated hemodialysis from 1988
and sixty ﬁve patients among them were over than 75 years. Their median
survival from initiation of hemodialysis was 29.02 (13.31-49.51) months.
The survival in patients whose HbA1c level was higher than 7.0% was lower
than in their counterpart (32.85 Vs 13.31 months; P¼0.0014).The patients
with AVBG and AVF showed much better survival compared to catheter
(36.75, 32.46 Vs 3.26 months; P¼0.0016). The patients over than 80 years
were 43% and their survival was much lower than the patients younger
than 80 years (16.00 Vs 36.75 months ; P¼0.0107). Cox regression analysis
showed the HbA1C 47.0% is independent prognostic factor. (HR¼4.66
(1.79-12.16), p¼0.002). In conclusion, Diabeus mellitus per se was not a
risk factor for mortality in this group. However untrolled diabetes mellitus
is independent prognostic factor for elderly ESRD patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.448125
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After PTX in 21HPT, appropriate calcium and calcitriol was supplied to
prevent hungry bone syndrome. Duration of admission was variable according
to multiple causes. We hypothesized the admission duration was mainly
affected by calcium requirement. The aims of this study were to evaluate PTX in
21HPT in single center and to make equation for calcium requirement. We
evaluated 91 patients with 94 PTX from Nov. 2003 to Dec.2011 in Korea Univ.
Guro Hospital. We retrieved demographic details including sex, age, body
weight, DM, hypertension, mode of renal replacement therapy, duration of
dialysis, duration of admission, mode of PTX, method of anesthetics, number of
glands removed, the largest gland length, the heaviest gland, and histologic
proﬁle of removed gland. We also gathered preoperative and postoperative (12
hrs and 48 hrs after PTX, discharge, 3 mo, 6 mo, 1 yr after PTX) laboratory data
such as calcium, phosphorus, iPTH, ALP, albumin, and Hb. We summated oral
and intravenous calcium supplement during hospitalization after PTX. We
prescribed oral calcitriol 2.0 mg/day after PTX. Statistical analysis was
performed with SPSS ver. 12.0.1. We could ﬁnd log(calcium total supplement
during admission) is correlated with preoperative ALP (p¼0.000), preoperative
iPTH (pþ0.037), and D phosphorus 48 hrs after PTX (p¼0.000) by multiple
linear regression. Log (calcium total supplement during admission) ¼ 2.576 þ
0.001 X preoperative ALP þ 3.575 X 10-5 X preoperative iPTH þ 0.06 X
Dphosphorus 48 hrs after PTX. We believe this equation would be helpful to
estimate calcium requirements after 48 hrs PTX and to give a clue about length
of hospitalization. We also would evaluate whether this equation is predictable
in our patients in the future.
http://dx.doi.org/10.1016/j.krcp.2012.04.449126
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Use of intradialytic oral nutritional supplements (ONS) improve
nutritional biomarkers but an association with survival has not been
proven. We evaluated mortality, comparing patients with serum albumin
r3.5 g/dL who received monitored ONS (at no patient cost) during chronic
outpatient hemodialysis (HD) as part of a standardized national program in
Fresenius Medical Care, North America facilities, with eligible patients who
did not receive ONS (controls). Participation was promoted but not
mandatory. Study enrolment covered Q42009 and followup was until 12/31/
10. Patients who received ONS outside of the program or started during 2010were excluded. Two protein bars and two liquid formulations of ONS options
were offered, which were available until albumin was Z 4.0 g/dL.
Crudemortality in the ONS group (N¼ 7,264) was 29.4% vs. 36.6% for controls
(N¼ 13,853), po0.001. Compared to controls, the unadjusted mortality hazard
ratio for ONS was 0.70 (0.67, 0.74) and after adjustment for baseline casemix
and 5 quality indicators was 0.68 (0.64, 0.71). Although limited by the
observational design, these results indicate favorable survival associated with
ONS use in malnourished chronic HD patients with albumin r3.5 g/dL.
http://dx.doi.org/10.1016/j.krcp.2012.04.450127
HOSPITALIZATION IS LESS IN MALNOURISHED PATIENTS GIVEN
INTRADIALYTIC ORAL NUTRITIONAL SUPPLEMENTS
Eduardo Lacson Jr., Weiling Wang, Barbara Zebrowski, Rebecca Wingard,
Raymond Hakim
Fresenius Medical Care, North America, Waltham, Massachusetts
Use of intradialytic oral nutritional supplements (ONS) improve nutritional
biomarkers but an association with hospitalization risk is unexplored. We
evaluated hospitalization events from all causes (HOS), comparing patients
with serum albumin r3.5 g/dL who received monitored ONS (at no patient
cost) during chronic outpatient hemodialysis (HD) as part of a standardized
national program in Fresenius Medical Care, North America facilities, with
eligible patients who did not receive ONS (controls). Study enrolment covered
Q42009 and followupwas until 12/31/10. Patients who received ONS outside of
the program or started during 2010 were excluded. Two protein bars and two
liquid formulations of ONS options were offered – – which were available until
albumin was Z 4.0 g/dL.
Overall, HOS was lower in the ONS group (N¼ 7,264) at 2.5 vs. 2.7 episodes/
ptyear for controls (N¼ 13,853), po0.001. The unadjusted time to 1st HOS
hazard ratio for ONS was 0.92 (0.88, 0.95) and after adjustment for baseline
casemix, HOS 30days prior to study entry, and 5 HD quality indicators was 0.93
(0.90, 0.96). Although limited by the observational design, these results indicate
lower HOS associated with ONS use in malnourished chronic HD patients with
albumin r3.5 g/dL.
http://dx.doi.org/10.1016/j.krcp.2012.04.451128
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Chronic kidney disease (CKD) is associated with a large range of metabolic
alterations. P-cresyl sulfate (PCS) has been identiﬁed as one of the main uremic
toxins involved in the pathogenesis of accelerated atherosclerosis in CKD. The
prebiotic soluble ﬁbers have the property of selectively stimulate growth and
activity of a limited number of beneﬁcial bacteria in the colon. The aim of this
study is to assess in mice the effects of prebiotics by the reduction of PCS
intestinal production, on metabolic disturbances associated with CKD.
Subtotally nephrectomized C57BL/6J wild-type mice were divided into two
groups: CKD mice and CKD mice fed with 5% (w/w standard diet) of prebiotic
arabinoxylane oligosaccharides (AXOS, WITAXOS SA,). Three weeks after
initiation of prebiotics serum cholesterol total, triglycerides, glucose, PCS were
measured. The insulin sensitivity was estimated by intra-peritoneal insulin
tolerance test and glucose tolerance test.
CKD mice treated with AXOS exhibited a signiﬁcant decrease in serum total
PCS (74%, p¼0.03). Prebiotic treatment reduced the loss of fat mass observed
in CKD (þ33%, po0.05). and prevented the ectopic lipid redistribution
associated with CKD. Prebiotic treatment completely prevented the expected
increase in glycemia, total cholesterol and triglycerides associated with CKD.
Insulin sensitivity was signiﬁcantly improved in prebiotic group.
These results suggest that prebiotics AXOS decrease PCS and prevented CKD-
induced insulin resistance, the loss of adipose tissue and prevented
accumulation of ectopic lipids in muscle and liver.. Because insulin resistance is
an important cardiovascular risk factor, novel therapeutic approaches like
prebiotics which could decrease PCS and cardio vascular mortality.
http://dx.doi.org/10.1016/j.krcp.2012.04.452
